KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Targeting the neuroimmune axis in prurigo nodularis: a critical appraisal of the nemolizumab trials.

Vito Di Lernia, Alberto Sticchi

Expert Opin Biol Ther 26(2) 103-107

PMID41712432
PMCID-
DOI10.1080/14712598.2026.2635517
发表日期2026-02-19
摘要

摘要

Background: Prurigo nodularis (PN) is a chronic, debilitating neuro-immunological skin disease characterized by intense pruritus and hyperkeratotic nodules. Nemolizumab, a novel IL-31 receptor alpha antagonist targeting the neural itch pathway, was investigated in PN.Areas covered: Two randomized phase 3 studies, the Olympia 1 and Olympia 2 trials, provided favorable efficacy and safety data for nemolizumab versus placebo in moderate-to-severe PN. After 16 weeks, a ≥4-point reduction in PP-NRS was achieved in 58.4% (Olympia 1) and 56.3% (Olympia 2) of nemolizumab patients compared to 16.7% and 20.9% in placebo groups, respectively (p<0.001). Safety data showed no drug-related serious adverse events or organ toxicity.Expert opinion: These trials were the first to clinically demonstrate IL-31 inhibition in PN. Nemolizumab represents a paradigm shift in PN therapy, acting as a potent "neuro-modulator" with rapid itch relief, often observed by Week 4.Conclusions: Future management may rely on disease endotypes to select between neural (IL-31) and immune (IL-4/13) blockade.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。